Combining advanced radiation therapies for treating relapsed neuroblastoma in children
COMBINATION HIGH-LET MOLECULAR RADIOTHERAPY OF RELAPSED REFRACTORY NEUROBLASTOMA
This study is testing a new way to treat relapsed neuroblastoma in kids by using a special type of radiation therapy combined with targeted medicines that focus on cancer cells, hoping to make treatment more effective and get rid of any tiny cancer cells that other treatments might miss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10979741 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment approach for relapsed neuroblastoma, a challenging childhood cancer. It aims to combine high linear energy transfer molecular radiotherapy with targeted agents that specifically attack cancer cells. By utilizing novel ligands that target specific biomarkers, the study seeks to improve the effectiveness of treatment and potentially eliminate microscopic cancer cells that traditional therapies may miss. The research will involve clinical trials to assess the safety and efficacy of this combination therapy in young patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who have been diagnosed with relapsed or refractory neuroblastoma.
Not a fit: Patients with neuroblastoma that has not relapsed or those over the age of 11 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates for children with relapsed neuroblastoma.
How similar studies have performed: Previous research has shown promising results with similar high-energy radiation therapies, indicating potential for success in this novel approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Zhang, Hanwen — Washington University
- Study coordinator: Zhang, Hanwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.